RBM15-MKL1融合蛋白通过m6A甲基化与Wnt通路激活促进白血病发生
研究探讨t(1;22)易位编码的RBM15-MKL1融合蛋白(RM)在急性巨核细胞白血病(AMKL)中的作用,采用多组学方法发现RM保留RBM15的RNA结合与m6A修饰功能并选择性调控Wnt通路Frizzled基因;METTL3抑制剂STM3675可诱导小鼠RM-AMKL细胞凋亡并延长移植小鼠生存,Frizzled敲低在体外和体内均减少RM-AMKL生长。
要点
- RM保留RBM15的RNA结合与m6A修饰功能,同时选择性调控Wnt通路Frizzled等mRNA靶点。
- METTL3抑制剂STM3675减少m6A沉积,体外诱导小鼠RM-AMKL细胞凋亡并延长移植小鼠生存。
- Frizzled基因受RM上调、METTL3抑制后下调,直接敲低Frizzled在体外和体内均减少RM-AMKL生长。
核心结论
- RM特异性m6A修饰与Wnt通路激活是RM-AMKL的关键驱动因素,这些通路为潜在治疗靶点。
研究设计与样本
- 采用多组学方法研究RBM15-MKL1融合蛋白(RM)在急性巨核细胞白血病(AMKL)中的作用。
- 使用小鼠RM-AMKL细胞进行体外实验,并在移植小鼠中评估生存。
- 原文未报告样本量。
主要发现
- RM保留RBM15的RNA结合与m6A修饰功能,同时选择性调控包括Wnt信号通路Frizzled基因在内的不同信使RNA靶点。
- METTL3抑制剂STM3675减少m6A沉积,体外诱导小鼠RM-AMKL细胞凋亡并延长移植小鼠生存。
- Frizzled基因受RM上调、METTL3抑制后下调,直接敲低Frizzled在体外和体内均减少RM-AMKL生长。
- 多种人AMKL中Wnt通路活性与Frizzled表达升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recurrent t(1;22) translocation in acute megakaryoblastic leukemia (AMKL) encodes the RBM15-MKL1 fusion protein. Dysregulation of the N6-methyladenosine (m6A) modification affects RNA fate and is linked to oncogenesis. Because RBM15 is critical for bringing the m6A writer complex to specific RNAs, we hypothesized that RM disrupts the m6A modification, thereby altering the RNA fate to drive leukemogenesis in RM-AMKL. Using a multiomics approach, we showed for the first time, to our knowledge, that RM retains the RNA-binding and m6A-modifying functions of RBM15 while also selectively regulating distinct messenger RNA targets, including Frizzled genes, in the Wnt signaling pathway. Treating murine RM-AMKL cells with the methyltransferase 3 (METTL3) inhibitor STM3675, which decreases m6A deposition, induced apoptosis in vitro and prolonged survival in transplanted mice. Frizzled genes were upregulated by RM and downregulated upon METTL3 inhibition, implicating an m6A-dependent mechanism in their dysregulation. Direct Frizzled knockdown reduced RM-AMKL growth in vitro and in vivo, highlighting Wnt signaling as a key oncogenic driver. Elevated Wnt pathway activity and Frizzled expression in multiple forms of human AMKL underscores the relevance of our findings. Together, our results establish that RM-specific m6A modifications and Wnt pathway activation are critical drivers of RM-AMKL, thereby identifying these pathways as potential therapeutic targets.
引用
- Mayday MY, Biancon G, Wei M, et al. RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and Wnt pathway activation. Blood. 2025. PMID: 40435410. doi:10.1182/blood.2024027712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。